Shots:

• The P- I/IIa study assess BI-1206 + rituximab in patients with indolent r/r B-cell NHL. The study consists of 2 parts: P- l with dose escalation cohorts using a 3+3 dose-escalation and selection of the recommended RP2D and P-IIa which is an expansion cohort at the RP2D enriched with MCL patients
• The results showed responses in 6/9 patients demonstrating BI-1206 has ability to restore activity of rituximab in NHL patients who have relapsed after treatment with rituximab
• Long-lasting complete responses observed in two patients beyond 12mos. The company has initiated P- I/IIa trial of BI-1808 in Jan’2020 and will initiate P- l/lla study of BT-001 in collaboration with Transgene

 ­ Ref: PRNewswire | Image: Nordic Life Science Insight